Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology firm focused on gene therapy, will have its CEO, Alfred W. Sandrock, Jr., present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET. The presentation will be available via webcast on the company's website and archived for 30 days. Voyager is known for its TRACER™ AAV capsid discovery platform, aiming to enhance gene therapy delivery, with ongoing projects in Alzheimer's, ALS, Parkinson's, and Friedreich's Ataxia.

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET.

A webcast of the presentation may be accessed from the Investors section of Voyager’s website at www.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER™ AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Friedreich’s Ataxia, each with validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Contacts
Investors
Andrew Funderburk
afunderburk@kendallir.com

Media
Peg Rusconi
prusconi@vergescientific.com

FAQ

What is Voyager Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Voyager Therapeutics will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023.

When is the Voyager Therapeutics presentation scheduled?

The presentation by Voyager Therapeutics is scheduled for January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET.

How can I access the Voyager Therapeutics conference presentation?

The presentation can be accessed through the Investors section of Voyager Therapeutics' website.

What is the focus of Voyager Therapeutics' research?

Voyager Therapeutics focuses on advancing gene therapy and neurology, with research in diseases like Alzheimer's and ALS.

What is the TRACER™ platform used by Voyager Therapeutics?

The TRACER™ platform is an AAV capsid discovery platform designed to improve gene therapy delivery and effectiveness.